HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SUPT6H
SPT6 homolog, histone chaperone and transcription elongation factor
Chromosome 17 · 17q11.2
NCBI Gene: 6830Ensembl: ENSG00000109111.16HGNC: HGNC:11470UniProt: Q7KZ85
133PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub GeneTransporter
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
transcription elongation-coupled chromatin remodelingprotein bindinghistone bindingtranscription elongation by RNA polymerase IIneurodegenerative diseaseAlzheimer diseaselysosomal storage diseasemultiple sclerosis
✦AI Summary

SUPT6H is a highly conserved histone chaperone and transcription elongation factor that plays multifaceted roles in gene regulation. As a histone H3-H4 chaperone, SUPT6H facilitates RNA polymerase II (RNAPII) elongation by binding to the phosphorylated C-terminal domain (CTD) of RNAPII and opening the RNA clamp formed by DSIF, thereby enabling pause release and productive transcription 1. SUPT6H functions as part of a regulatory complex with IWS1 that coordinates transcription elongation with mRNA processing and export by recruiting export factors and histone-modifying enzymes like SETD2, ensuring H3K36 methylation during active transcription 2. Beyond elongation, SUPT6H regulates epigenetic remodeling through interaction with KDM6A to erase repressive H3K27me3 marks and maintains ERα-driven transcription in breast cancer cells through histone H2B monoubiquitination regulation 3. Clinically, SUPT6H emerges as a prognostic factor in breast cancer, with protein levels decreasing with malignancy and correlating with cellular differentiation 3. Additionally, SUPT6H has been identified as a platinum-resistance-related gene in ovarian cancer, contributing to a predictive signature for chemotherapy response 4. Recent evidence suggests SUPT6H protects cardiomyocytes from angiotensin II-induced hypertrophy through a miR-423-5p regulatory pathway 5.

Sources cited
1
SPT6 binds to phosphorylated Pol II CTD and opens the RNA clamp to release pause and activate transcription elongation
PMID: 30135578
2
SPT6/SUPT6H recruits IWS1 to the phosphorylated CTD, linking transcription elongation with mRNA export and histone modifications
PMID: 18513937
3
SUPT6H is required for estrogen-regulated transcription and cellular differentiation through regulation of H2Bub1 and H3K27me3 suppression; levels decrease with breast cancer malignancy
PMID: 24441044
4
SUPT6H is part of a platinum-resistance-related gene signature predictive of ovarian cancer chemotherapy response
PMID: 39901543
5
SUPT6H is a target of miR-423-5p and protects cardiomyocytes from angiotensin II-induced hypertrophy and oxidative stress
PMID: 36517015
6
SUPT6H is the highly conserved human homolog of yeast SPT6, located on chromosome 17q11.2, with roles in transcriptional regulation through chromatin structure
PMID: 8786132
7
SPT6 is a major elongation factor that allows Pol II to move through nucleosomes
PMID: 24050178
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.49Moderate
Alzheimer diseaseOpen Targets
0.46Moderate
lysosomal storage diseaseOpen Targets
0.46Moderate
multiple sclerosisOpen Targets
0.46Moderate
Parkinson diseaseOpen Targets
0.46Moderate
neoplasmOpen Targets
0.08Suggestive
colorectal carcinomaOpen Targets
0.07Suggestive
Barrett's esophagusOpen Targets
0.06Suggestive
glioblastoma multiformeOpen Targets
0.06Suggestive
placenta praeviaOpen Targets
0.03Suggestive
cancerOpen Targets
0.02Suggestive
goutOpen Targets
0.02Suggestive
esophageal adenocarcinomaOpen Targets
0.02Suggestive
glioblastomaOpen Targets
0.02Suggestive
laryngeal squamous cell carcinomaOpen Targets
0.01Suggestive
gliomaOpen Targets
0.01Suggestive
esophageal squamous cell carcinomaOpen Targets
0.01Suggestive
infectionOpen Targets
0.01Suggestive
Nijmegen breakage syndromeOpen Targets
0.01Suggestive
osteosarcomaOpen Targets
0.01Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
CHD1Protein interaction100%POLR2AProtein interaction100%POLR2BProtein interaction100%POLR2CProtein interaction100%POLR2DProtein interaction100%POLR2GProtein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Lung
96%
Brain
93%
Liver
91%
Ovary
88%
Heart
70%
Gene Interaction Network
Click a node to explore
SUPT6HCHD1POLR2APOLR2BPOLR2CPOLR2DPOLR2G
PROTEIN STRUCTURE
Preparing viewer…
PDB6GME · 1.80 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.08Highly Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.05 [0.03–0.08]
RankingsWhere SUPT6H stands among ~20K protein-coding genes
  • #3,500of 20,598
    Most Researched133 · top quartile
  • #22of 17,882
    Most Constrained (LOEUF)0.08 · top 1%
Genes detectedSUPT6H
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Identification and analysis of the human and murine putative chromatin structure regulator SUPT6H and Supt6h.
PMID: 8786132
Genomics · 1996
1.00
2
Structure of activated transcription complex Pol II-DSIF-PAF-SPT6.
PMID: 30135578
Nature · 2018
0.90
3
MiR-423-5p Inhibition Exerts Protective Effects on Angiotensin II-Induced Cardiomyocyte Hypertrophy.
PMID: 36517015
Tohoku J Exp Med · 2023
0.80
4
The plasma peptides of sepsis.
PMID: 32636717
Clin Proteomics · 2020
0.70
5
SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms.
PMID: 24441044
Oncogene · 2015
0.60